Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy back in mid-2021.Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, however, so is there any chance it could ascend those lofty heights again?Novo Nordisk bears would be quick to point a paw at the company's so far sole competitor in the GLP-1 race, Eli Lilly.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool